Glaxo drug candidate may boost platelet count

11/28/2007 | Forbes

Scientists found that the experimental drug eltrombopag, marketed by GlaxoSmithKline as Promacta, can increase blood platelet levels and reduce the risk of bleeding. Their findings are based on two studies. One was of patients with the autoimmune disorder idiopathic thrombocytopenic purpura, while the other observed patients with hepatitis C-related cirrhosis of the liver.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX